News Releases

Vyaire Medical Issues Voluntary Correction for Certain bellavista™ Ventilators in Specific Software Configurations

February 4, 2022

CHICAGO, February 4, 2022—In December 2021, imtmedical ag, a subsidiary of Vyaire Medical, initiated a voluntary field correction for certain bellavista™ ventilators. With specific software version and configuration combinations, the ventilators can cease ventilation and generate a technical failure alarm 305. There is a potential issue with bellavista™ 1000 and 1000e ventilators that have software version 6.0.1600.0 or higher installed, which was deployed in February 2021, and also have the Data Communication port set to “HL7”. Customers with software version 6.0.1600.0 or higher installed have been notified by Vyaire to immediately disable the HL7 data communication if activated. If the HL7 data communication is not disabled, such devices are at risk of the reported unintentional ceasing of ventilation. This decision is based on the receipt of reports that some bellavista™ 1000 and 1000e ventilators have unintentionally ceased ventilation during clinical use and require rebooting to resume ventilation due to a software issue. An internal investigation determined that bellavista 1000 and 1000e ventilators with software version 6.0.1600.0 or higher installed can have a conflict in memory resource allocation between software tasks when the Data Communication port is set to “HL7”. The ventilator notifies the user of the issue by triggering technical failure alarm 305 indicating an interruption in the communication between the user interface controller (EPC) and the ventilation controller (CFB). No patient harm has been reported related to this issue. If clinicians operate a bellavista™ ventilator and do not set Data Communication port to “HL7”, this error will not occur. Therefore, Vyaire supports the continued use of these devices and directs customers to follow the instructions provided in the Company’s correction notification to immediately disable the HL7 data communication if activated while the company develops and deploys a software update to address the issue, anticipated in Q1 of calendar year 2022. The affected ventilators were distributed to medical facilities in the US between 3/21/19 through 12/23/21 located in the following states: AL, CA, CO, CT, DC, FL, GA, ID, IL, IN, LA, MA, MD, MI, MO, MS, NC, NJ, NY, OH, OK, PA, PR SD, TX, VA, WA, WI and WV. US customers with questions about this correction should call 833-327-3284 between 5 am and 5 pm PST Monday through Friday, or email GMB-AMS-FSCAresponsecentre@vyaire.com. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 At Vyaire, patient safety is of the utmost importance, and this voluntary correction is part of our commitment to the highest quality standards for the people who rely on our technology around the world. About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

The new SuperNO2VA™ Et mask establishes a new care paradigm for surgical options by maintaining an open airway and providing real-time exhaled carbon dioxide monitoring, decreasing sedation risk before, during and after surgery

Vyaire Medical Advances Surgical Sedation Safety with Novel Airway Technology for All Patient Risk Levels

October 29, 2021

The new SuperNO2VA™ Et mask establishes a new care paradigm for surgical options by maintaining an open airway and providing real-time exhaled carbon dioxide monitoring, decreasing sedation risk before, during and after surgery CHICAGO, October 29, 2021—Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the availability of SuperNO2VA™ Et, a mask that utilizes breakthrough technology to stent the airway open, thus avoiding airway collapse while accurately monitoring end tidal carbon dioxide (EtCO2), which is particularly important for high-risk patients. It uniquely maintains airway patency while delivering precise and consistent oxygenation to patients during deep sedation procedures, helping reduce hypoxemia and hypoventilation. SuperNO2VA™ Et provides increased flexibility by providing continuous patient oxygenation before, during and after surgery, and transforms surgical practice by allowing more patients to have procedures under sedation. “At Vyaire, we are committed to imagining new possibilities in the ways we can support breathing. SuperNO2VA™ Et does just that by removing some of the tangible risks of deep sedation through proprietary airway management technology and real-time clinical measurements to reduce complications,” said Gaurav Agarwal, chief executive officer, Vyaire. “Through this innovation, we envision reducing the need for general anesthesia and the associated complications, including extended procedure times, hospital stays and their burdens on healthcare systems.” SuperNO2VA™ Et reduces hypoxemia by 75 percent and airway intervention by 65 percent compared to current standard of care.i ii It also allows for effective pre-oxygenation and rescue ventilation without the need for additional equipment, and eliminates the use and associated costs of a separate mask, endotracheal tube, laryngoscope and intubation. “SuperNO2VA™ Et brings a new standard to the way surgeries can be performed for patients,” said Steven H. Cataldo, MD, director of anesthesiology at CareMount Medical and director of anesthesia services at Yorktown Center for Specialty Surgery. “With this technology, we are able to rethink how and where we operate, with decreased risks, procedure times and associated costs. Even high-risk patients can have reduced recovery times, providing them a safer and better overall care experience.” “As the company inspired and empowered to elevate the quality of breathing, SuperNO2VA™ Et is an obvious yet critical piece of our innovation strategy and evolution,” said Agarwal. “We will continue to bring new-to-world technology to market to advance breathing solutions on behalf of customers and patients.” About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.   i Bai Y, Xu Z, Chandrashekar M, at al. Comparison of a simplified nasal continuous positive airways pressure device with nasal cannula in obese patients undergoing colonoscopy during deep sedation: A randomised clinical trial. Eur J Anaesthesiol. 2019;36(9):633-640. ii Dimou F, Huynh S, Dakin G, et al. Nasal positive pressure with the SuperNO2VA™ Et device decreases sedation-related hypoxemia during pre-bariatric surgery EGD. Surg Endosc. 2019;33(11):3828-3832.

Vyaire Medical Advances the Standard of Care in Low-Flow Oxygen Delivery

July 28, 2021

The new AirLife™ Open oxygen mask provides the benefits of traditional cannula, mask and non-rebreather devices into a single revolutionary solution for low-flow oxygen therapy CHICAGO, July 28, 2021—Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the availability of AirLife™ Open oxygen mask, a revolutionary new low-flow oxygen therapy device designed to advance the standard of care and improve the satisfaction of patients receiving low-flow oxygen therapy. The AirLife™ Open oxygen mask combines the best elements of traditional nasal cannula, oxygen mask and non-rebreather benefits in a single device that is revolutionary for low-flow oxygen therapy. This is achieved through the patented design and unique geometry of the mask openings that maintain higher oxygen concentrations without obtrusive structures. The mask’s design distributes oxygen flow through unique jet orifices, creating a soft curtain of oxygen around the nose and mouth, reducing the risk of rebreathing carbon dioxide resulting in a more comfortable patient experience. The AirLife™ Open mask is designed to allow patients to drink, eat and easily communicate without removing the mask, while delivering uninterrupted oxygen therapy. For clinicians, AirLife™ Open provides the ability to adjust oxygen delivery from 1—15 LPM without disturbing the patient. What’s more, the unique design of AirLife™ Open allows access for certain procedures and the easy transfer of patients between areas of care. AirLife™ Open reduces the need to change out interfaces, improving workflow, reducing waste and cost while effectively delivering continuous oxygen therapy without compromising safety or quality.   “Vyaire is leveraging our rich history of innovation and expansive knowledge in respiratory care to bring to market revolutionary devices like the AirLife™ Open mask that will advance patient comfort and care while reducing the burden on clinicians,” said Gaurav Agarwal, chief executive officer, Vyaire. “We incorporated feedback from customers and patients from across the world and we are thrilled that the results we have seen confirm that the new design delivers the revolutionary benefits AirLife™ Open provides.” “The novel design of AirLife™ Open is the culmination of customer inputs and extensive benchtop testing,” said Michael Pedro, M.D., chief medical officer, Vyaire, and board-certified anesthesiologist. “The feedback from our limited commercial release exceeds our initial expectations as AirLife™ Open is delivering superior results both in maintaining oxygen concentrations and reducing the risk of rebreathing while providing patients with an enhanced, updated and more comfortable method of oxygen therapy.” “We believe that when it comes to compliance and comfort, there shouldn’t be a tradeoff. AirLife™ Open is the first of many new innovations Vyaire will introduce that are patient-centric and improve the standard of care,” added Agarwal. “For far too long, innovation within the respiratory space has been dormant, and Vyaire is working to fill that void, bringing meaningful new consumable products to market that will help everyone breathe better.” About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Medical Expands Ability to Streamline Respiratory Care Through Portable Remote Monitoring and Connectivity Capabilities

June 28, 2021

Vyaire signals significant strategic investment in digital technology and data management capabilities with launch of new tool that helps clinicians provide life-saving care CHICAGO, June 28, 2021—Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the development of a new comprehensive digital tool designed to arm clinicians with the data and insights they need to better manage breathing for critically ill patients. Vyaire Messenger is a novel mobile application that securely provides patient status information and meaningful clinical insights directly to the respiratory therapist via their mobile devices. Vyaire Messenger is intended to reduce the burden on clinicians by providing visibility to all ventilated patients simultaneously so that they can prioritize and coordinate care. In addition, Vyaire Messenger will proactively notify clinicians should a patient experience a change in ventilation therapy, simplifying processes and prioritizing patients who need the most care. “Vyaire is leveraging digital and connectivity technology to reimagine the needs of our customer base,” said Gaurav Agarwal, chief executive officer of Vyaire. “Our collective experience with COVID-19 has taught us that care must be delivered differently, such as the ability to better triage patients or monitor them outside the hospital room. We are committed to taking those lessons learned and delivering meaningful solutions that help clinicians provide care to those who need it most.” Vyaire Messenger works seamlessly with the bellavista™ and Avea™ ventilation platforms via the Respiratory Knowledge Portal, a data application system released by Vyaire in 2015. The Vyaire Messenger is unique to market in that it is portable on mobile devices and gathers data from compatible IV pumps providing important clinical insights in sedation. Developed in partnership with customers on the front lines, Vyaire Messenger has the potential to significantly reduce the cost of care in the ICU by improving protocol adherence and coordination of clinical functions in order to reduce the amount of time patients spend on a ventilator. The Company released Vyaire Messenger last summer to a limited market and developed the current version based on customer testing and feedback. Clinical data gathered from that period enhances the Company’s thesis that Vyaire Messenger has the potential to improve multiple metrics & outcomes, including[1]: 78% of clinicians who agree that Vyaire Messenger has the potential to improve protocol adherence resulting in an improvement in ventilated patient outcomes; 83% of clinicians who agree that Vyaire Messenger has the potential to improve coordination of care between clinical functions resulting in the reduction of the incidences of ventilator associated events (VAE).  “Monitoring and prioritizing ventilated patients without these advanced technologies requires frequent bedside visits and coordination of care between various clinical specialties is a challenge,” said Tom Cahill, Respiratory Director at St. Elizabeth Healthcare in Kentucky. “Now, our clinicians can get real-time clinical insights for their patients right at their fingertips and improved communication within our care teams, which helps prioritize patient care and provide optimal patient management.” “With the availability of Vyaire Messenger, we are embarking on an exciting digital transformation journey,” continued Agarwal. “Vyaire engineers are hard at work contemplating how we will leverage digital and connectivity technology across sedation, diagnostics and ventilation platforms. We see exciting potential in this space that will help patients around the world take better breaths.” About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.   [1] Vaire Messenger Pilot Study Report, Integritas Analytics, 2021

Vyaire Medical Debuts New Corporate Brand Affirming Commitment to Innovation that Enhances Quality of Breathing

April 14, 2021

New Look Reflects Longstanding Legacy of Respiratory Care and Elevates Passion, Ingenuity and Dedication to Improving the Quality of Every Breath CHICAGO, April 14, 2021—Vyaire Medical, the world’s largest medical device maker fully dedicated to improving breathing for every person around the world, today announced the launch of its new corporate brand identity as part of its transformational efforts to rapidly innovate leading-edge products and services that enable, enhance and extend every breath. “Breathing is instinctual and too often we take for granted the importance until there is an issue,” said Gaurav Agarwal, chief executive officer of Vyaire. “As the past year has shown, every single breath is vital to the health and well-being of people of all ages. Our new brand identity is meant to acknowledge that notion and reflect the passion and urgency Vyaire brings to market through solutions that enhance and support breathing through every stage of life.” As We Live and Breathe The breadth and scale of the Vyaire portfolio is unmatched anywhere in the world. The Company’s new tagline highlights Vyaire’s leadership beyond the traditional respiratory space, signaling the broadest portfolio of breathing solutions supporting the care continuum from diagnostics to consumables to ventilation. More than that, it demonstrates a renewed commitment to clinicians that Vyaire is a trusted partner in their quest to advance the science of breathing and improve outcomes for their patients. “As we live and breathe” is an homage to patients, that Vyaire is here to ensure that every day — and every breath — is lived to the fullest. It’s also a pledge to healthcare professionals who care for patients that Vyaire provides products to help enable and ensure optimal breathing. The revitalized brand identity features a refreshed logo, new brand hallmark and a bold new color palette. The new brand hallmark represents the lungs, a subtle reminder of the Company’s purpose; the gradients of red and blue evoke leadership, passion, urgency and trust. As part of the reboot, Vyaire is debuting a new corporate marketing campaign, “Because I Can Breathe,” which pays tribute to how better breathing empowers people to pursue their passions and achieve their goals. Vyaire is launching a new corporate website to showcase the “Because I Can Breathe” campaign and new brand identity. The updates mark a significant milestone for Vyaire as it evolves from a 65-year history of pioneering technology from well-known respiratory brands into a unified global organization solely dedicated to breathing. “Our new brand identity signals an exciting new era for Vyaire,” continued Agarwal. “It is much more than a cosmetic change – it represents the drive and determination of close to 5,000 employees around the globe working to drive innovation because we know that our customers and their patients require the best solutions. I want our new identity to reflect that urgency and the creativity my colleagues bring to the work they do every day.” About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Medical Advances into Artificial Intelligence-Supported Respiratory Diagnostics with New Tool

April 7, 2021

CHICAGO, April 07, 2021—Vyaire Medical today announced the European launch of ArtiQ.PFT, an automated tool driven by artificial intelligence that instantly interprets pulmonary function tests (PFTs). The technology’s algorithms detected disease pattern in 82 percent of cases, compared to 45 percent by pulmonologists, according to a multi-center study published in the European Respiratory Journal.[1] “Vyaire is at the forefront of incorporating the latest digital technology to ensure people’s breathing needs are met,” said Gaurav Agarwal, chief executive officer of Vyaire. “By introducing this technology, we can help clinicians feel confident in their diagnosis at the outset, enhancing their patients’ care from the start.” ArtiQ.PFT is the first cloud-based PFT-solution that leverages artificial intelligence. Prior to ArtiQ.PFT, pulmonologists spent a significant number of hours each week interpreting lengthy data to establish a diagnosis. This technology provides a standardized and unbiased diagnostic interpretation in seconds, allowing clinicians to focus on clinical decision making and patient consult. “Getting to the right treatment plan as soon as possible is critical for patients, and this technology helps clinicians reduce redundant testing and get people the care they need faster,” said Michael Pedro, M.D., vice president and medical director of Vyaire. “ArtiQ.PFT can help minimize time lost due to misdiagnosis, the ramifications of which are significant, particularly as we look ahead to a potential increase of individuals with long-term lung damage as a result of the COVID-19 pandemic.” Through a partnership with Belgian-based ArtiQ, ArtiQ.PFT is now integrated into SentrySuite™ in Europe, the software platform for all Vyntus™ Pulmonary Function Systems. SentrySuite provides an automated workflow process that seamlessly connects with existing networks and clinical infrastructures. About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Medical Launches Novel Remote AioCare Mobile Spirometer

March 16, 2021

CHICAGO, March 16, 2021—Vyaire Medical today announced the launch of the AioCare (HealthUp SA, Poland) mobile spirometry system in more than 15 countries across Europe, the Middle East, and Australia. This clinically proven technology expands upon Vyaire’s deep respiratory diagnostics expertise and allows physicians to promptly diagnose pulmonary diseases including asthma and COPD as accurately as hospital-grade spirometers. It also performs high-quality patient monitoring via advanced digital connectivity at home. “At Vyaire we are committed to advancing respiratory care, delivering new innovation that expands the clinician’s ability to diagnose and treat breathing disorders,” said Gaurav Agarwal, chief executive officer of Vyaire. “The AioCare mobile spirometry system is the latest example of our determination to enhance patients’ lives with new, easy-to-use technology that offers digitally-connected monitoring and care for chronic respiratory diseases in the comfort of their homes.” “Early diagnosis of COPD is critical to preventing disease escalation and maintaining patients’ quality of life, but many general practitioners and primary care physicians find it difficult to diagnose. AioCare’s algorithm guides physicians and provides them with confidence,” said Michael Pedro, M.D., vice president and medical director of Vyaire. “Further, at-home monitoring is critical for providing patients safe and continuous care at home, particularly now in the midst of the COVID-19 pandemic.” AioCare consists of a portable spirometer connected to a dedicated smartphone app and an online panel that allows physicians and patients to share and discuss results through remote tracking and secure communication. Dedicated algorithms measure lung parameters and symptoms and provide real-time results, allowing chronic respiratory patients to avoid unexpected consequences of disease exacerbation when self-monitoring. The AioCare digital health technology will also integrate with Vyaire’s SentrySuiteTM software platform, offering healthcare providers more context and information about each patient’s unique respiratory condition. Worldwide, an estimated 251 million COPD patients and 339 million asthma patients are undiagnosed. Asthma and COPD put enormous economic burdens on healthcare systems across the globe. Having the right tools to assist in early diagnosis and ongoing treatment are critical to reducing those costs. Under the agreement with HealthUp SA, Vyaire will begin distributing AioCare in the first 15 countries this month, with additional market registrations pending. About Vyaire Medical Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.

Vyaire Signs Framework Contract with European Commission for Delivery of Ventilators in Response to COVID-19 Pandemic

May 14, 2020

CHICAGO – May 14, 2020 – Vyaire Medical Inc., the world’s largest healthcare company fully dedicated to respiratory care, announced today that Vyaire has been selected by the European Commission as a supplier of priority medical equipment to help address the COVID-19 pandemic. Under a framework contract Vyaire will be providing ventilators to EU Member States. The framework contract runs for 12 months and allows for the purchase of approximately 26,200 ventilators in total, based on ordering by the Member States. “Vyaire is meeting the global challenge posed by the COVID-19 pandemic, working hand in glove with governments around the world to ensure an adequate supply of ventilators and associated equipment immediately and in the months to come,” said CEO Gaurav Agarwal. “This framework contract offers a seamless purchasing path for EU member states to increase their supply of critical ventilation equipment needed as the COVID-19 pandemic evolves.” Vyaire participated in a European Commission tender seeking production of invasive and non-invasive ventilators, including its bellavista™ and bellavista™ 1000e models. Early in the crisis, Vyaire responded quickly to the urgent needs in Europe by leveraging its global distribution network to deliver bellavista™ units to the hard-hit areas at the center of the outbreak. Since then, Vyaire has been working closely with governments around the globe, suppliers and manufacturing partners to considerably increase production capacity to meet the needs of the pandemic. Vyaire’s center of European operations is based in Basingstoke, England, and the company has direct presence in six other EU countries. Its workforce within the EU consists of more than 500 people and 100 business partners and distributors.  About Vyaire Medical: Vyaire is one of the largest global manufacturers of invasive and noninvasive ventilators and other breathing equipment purely focused on delivering solutions for respiratory care. Vyaire has been selected by the European Commission as a supplier of priority medical equipment to help address the COVID-19 pandemic, including as many as 26,200 bellavista™ ventilators and associated consumable products.  Vyaire has been present in Europe since 1954 with manufacturing in Krugzell and Höchberg, Germany and Hirzel and Buchs, Switzerland with research and innovation centers based in Höchberg, Germany, Hirzel, Switzerland and Helsinki, Finland. The bellavista™ ventilation portfolio offers hospitals a comprehensive solution with integration of high flow oxygen therapy and advanced synchrony support for neonatal to adult patients in a single device. Clinicians can rapidly change therapies on a broad range of patients in an effortless way.  Vyaire sells its products in all 27 EU member states and more than 100 countries globally outside of the United States, through a direct sales force, and indirect sales channels, fulfilled by its network of more than 400 distributors and business partners. For more information, please visit our website, which will be updated as our pandemic response evolves: Vyaire COVID-19 Response Center. About Vyaire Medical Vyaire Medical Inc., a global company dedicated to respiratory care, enables, improves and extends lives with an unyielding focus on improving patient outcomes and increasing value for customers. The company consists of a conglomeration of well-known brands and was formed in October 2016 to serve healthcare providers with innovative devices and service solutions across the respiratory and anesthesia continuum of care. Headquartered in suburban Chicago, Vyaire’s legacy brands have a 65-year track record of pioneering and advancing respiratory diagnostics, ventilation, and anesthesia delivery & monitoring. From original brands — including Bird, Bear, and JAEGER to industry leaders AirLife™, Vital Signs™, Viasys, and many others — Vyaire Medical is recognized, trusted and preferred by specialists in respiratory and anesthesiology healthcare worldwide. Learn more at www.vyaire.com. Contact Cheston Turbyfill VP Corporate Communications Email: Cheston.Turbyfill@vyaire.com

2 of 4

Vyaire Medical Completes Business Unit Sales

Vyaire has completed transactions with ZOLL Medical Corporation and Trudell Medical Limited.

Learn More